Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.46 USD
Change Today +0.07 / 2.93%
Volume 323.9K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

transenterix inc (TRXC) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - $4.87
52 Week Low
12/15/14 - $1.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSENTERIX INC (TRXC)

Related News

No related news articles were found.

transenterix inc (TRXC) Related Businessweek News

No Related Businessweek News Found

transenterix inc (TRXC) Details

TransEnterix, Inc., a medical device company, focuses on the development and commercialization of a robotic assisted surgical system in the United States and internationally. The company develops SurgiBot System, a single-incision, patient-side robotic-assisted surgery system. The SurgiBot System comprises of SurgiBot Base, a reusable robotic base that provides the platform of the system; the EndoDrive, a single port, surgical access device for abdominal surgery; and the Positioning Arm, a reusable arm that supports and repositions the SurgiBot Base at the operating table. The company also develops and manufactures flexible and rigid laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, flexible energy device, and suction and irrigation instruments. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

98 Employees
Last Reported Date: 02/20/15

transenterix inc (TRXC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $282.8K
Compensation as of Fiscal Year 2014.

transenterix inc (TRXC) Key Developments

TransEnterix, Inc. Amends Existing Loan Agreement with Oxford Finance LLC and Silicon Valley Bank

TransEnterix, Inc. announced that it has expanded its existing financing agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) to provide for up to $30.0 million in growth capital, an increase from $25.0 million. On August 14, 2015, the company entered into an amendment to its amended and restated loan and security agreement (the Loan Agreement) with Oxford and SVB for a total loan amount of up to $30.0 million. At closing, due to the achievement of certain milestones, the Company increased its existing borrowings to $20.0 million, up from $10.0 million. The availability of the third tranche of $10.0 million is dependent upon the company achieving certain milestones specified in the loan agreement. The loan will mature on October 1, 2018, or April 1, 2019, if certain milestones are achieved. The company is entitled to make interest only payments until May 1, 2016. The interest-only period is extended to November 1, 2016 if the company receives 510(k) clearance for its SurgiBot System at any time prior to April 30, 2016. The loan agreement includes customary warrant coverage and is secured by company assets. Proceeds will be used for general corporate and working capital purposes.

TransEnterix, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

TransEnterix, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss of $9,068,000 against $10,381,000 a year ago. Net loss was $9,348,000 against $10,587,000 a year ago. Net loss per basic and diluted share was $0.14 against $0.18 a year ago. For the six months, the company reported operating loss of $18,907,000 against $17,539,000 a year ago. Net loss was $19,468,000 against $18,066,000 a year ago. Net loss per basic and diluted share was $0.30 against $0.33 a year ago. Net cash and cash equivalents used in operating activities was $16,126,000 against $13,362,000 a year ago. Purchase of property and equipment was $311,000 against $910,000 a year ago.

TransEnterix, Inc. to Report Q2, 2015 Results on Aug 06, 2015

TransEnterix, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRXC:US $2.46 USD +0.07

TRXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Intuitive Surgical Inc $514.24 USD -1.33
Johnson & Johnson $95.17 USD -1.05
Medtronic PLC $73.56 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation TRXC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 859.2x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 651.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSENTERIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at